

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Breast cancer	Cyclin dependent kinase 2 (CDK2); cyclin E (CCNE); HER2 (EGFR2; ERBB2; neu)	<p><i>In vitro</i> and mouse studies suggest that CDK2 inhibitors could help treat drug-resistant, HER2-positive breast cancers. Herceptin-resistant, HER2-positive cancer cell lines had greater expression of CCNE and more CCNE-CDK2 kinase activity than nonresistant, HER2-positive cancer cell lines. In mice with Herceptin-resistant xenografts, Herceptin plus a CDK2 inhibitor decreased tumor growth better than either agent alone. Next steps could include additional animal studies to determine the safety and efficacy of the combination.</p> <p>Roche's Genentech Inc. unit markets Herceptin trastuzumab, an anti-HER2 antibody, to treat breast and gastric cancers. At least 25 other companies have therapeutics targeting HER2 in development stages ranging from preclinical to marketed to treat cancer.</p> <p><b>SciBX 4(9); doi:10.1038/scibx.2011.247</b>  <b>Published online March 3, 2011</b></p>	Patent and licensing status unavailable	<p>Scaltriti, M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 14, 2011; doi:10.1073/pnas.1014835108</p> <p><b>Contact:</b> José Baselga, Harvard Medical School, Boston, Mass.  e-mail: <a href="mailto:jbaselga@partners.org">jbaselga@partners.org</a></p>